FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996079955> ?p ?o ?g. }

• W2996079955 endingPage "S903" @default.
• W2996079955 startingPage "S903" @default.
• W2996079955 abstract "This analysis aimed to estimate the cost per responder in the United Kingdom (UK) of two innovative treatments, guselkumab and secukinumab, leveraging treatment cost data and head-to-head efficacy results from the Phase 3 ECLIPSE clinical trial. A cost per responder model was developed using efficacy data from ECLIPSE to inform treatment response. Treatment response definitions included: achievement of 90% improvement in baseline Psoriasis Area and Severity Index (PASI) score (ie, PASI 90 response), PASI 100 response, or an Investigator’s Global Assessment (IGA) score of 0/1 (cleared/minimal). Only drug costs were considered, based on European Medicines Agency Summary of Product Characteristics dosing and 2019 UK list prices as published in the British National Formulary. The analyses were conducted at Week 48 (PASI 90 response, PASI 100 response, and IGA score 0/1) and from Week 12 to 48 (PASI 90). At Week 48, guselkumab was associated with a significantly higher PASI 90 response rate (84.5% vs. 70.0%, p<0.001) and lower overall drug costs (£15,750 vs. £17,063) than secukinumab, leading to a lower cost per PASI 90 responder (£18,639 vs. £24,376). Similarly, guselkumab had lower costs per PASI 100 and IGA 0/1 responder at Week 48 (£27,062 vs. £35,254 and £18,529 vs. £22,781, respectively). Additionally, guselkumab had a lower cost per PASI 90 responder at all timepoints assessed from Week 12 to Week 48. Based on data from the ECLIPSE trial, guselkumab had a lower cost per responder than secukinumab across all responder definitions and timepoints evaluated. The use of guselkumab in place of secukinumab could result in cost savings of £4,252 to £8,192 per responder after 48 weeks of treatment. These results suggest that guselkumab offers greater economic value than secukinumab in the treatment of moderate to severe plaque psoriasis through approximately one year of treatment." @default.
• W2996079955 created "2019-12-26" @default.
• W2996079955 creator A5006373941 @default.
• W2996079955 creator A5014379360 @default.
• W2996079955 creator A5043610709 @default.
• W2996079955 creator A5078157704 @default.
• W2996079955 date "2019-11-01" @default.
• W2996079955 modified "2023-09-30" @default.
• W2996079955 title "PSY12 COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS BASED ON THE ECLIPSE TRIAL" @default.
• W2996079955 doi "https://doi.org/10.1016/j.jval.2019.09.2640" @default.
• W2996079955 hasPublicationYear "2019" @default.
• W2996079955 type Work @default.
• W2996079955 sameAs 2996079955 @default.
• W2996079955 citedByCount "1" @default.
• W2996079955 countsByYear W29960799552020 @default.
• W2996079955 crossrefType "journal-article" @default.
• W2996079955 hasAuthorship W2996079955A5006373941 @default.
• W2996079955 hasAuthorship W2996079955A5014379360 @default.
• W2996079955 hasAuthorship W2996079955A5043610709 @default.
• W2996079955 hasAuthorship W2996079955A5078157704 @default.
• W2996079955 hasBestOaLocation W29960799551 @default.
• W2996079955 hasConcept C126322002 @default.
• W2996079955 hasConcept C16005928 @default.
• W2996079955 hasConcept C2776260265 @default.
• W2996079955 hasConcept C2777011040 @default.
• W2996079955 hasConcept C2779786854 @default.
• W2996079955 hasConcept C2780564577 @default.
• W2996079955 hasConcept C3020604521 @default.
• W2996079955 hasConcept C535046627 @default.
• W2996079955 hasConcept C71924100 @default.
• W2996079955 hasConceptScore W2996079955C126322002 @default.
• W2996079955 hasConceptScore W2996079955C16005928 @default.
• W2996079955 hasConceptScore W2996079955C2776260265 @default.
• W2996079955 hasConceptScore W2996079955C2777011040 @default.
• W2996079955 hasConceptScore W2996079955C2779786854 @default.
• W2996079955 hasConceptScore W2996079955C2780564577 @default.
• W2996079955 hasConceptScore W2996079955C3020604521 @default.
• W2996079955 hasConceptScore W2996079955C535046627 @default.
• W2996079955 hasConceptScore W2996079955C71924100 @default.
• W2996079955 hasLocation W29960799551 @default.
• W2996079955 hasOpenAccess W2996079955 @default.
• W2996079955 hasPrimaryLocation W29960799551 @default.
• W2996079955 hasRelatedWork W2756813587 @default.
• W2996079955 hasRelatedWork W2895404113 @default.
• W2996079955 hasRelatedWork W2954778191 @default.
• W2996079955 hasRelatedWork W3081271718 @default.
• W2996079955 hasRelatedWork W3101847676 @default.
• W2996079955 hasRelatedWork W3158109123 @default.
• W2996079955 hasRelatedWork W3190411311 @default.
• W2996079955 hasRelatedWork W3195419806 @default.
• W2996079955 hasRelatedWork W4255680485 @default.
• W2996079955 hasRelatedWork W4297878981 @default.
• W2996079955 hasVolume "22" @default.
• W2996079955 isParatext "false" @default.
• W2996079955 isRetracted "false" @default.
• W2996079955 magId "2996079955" @default.
• W2996079955 workType "article" @default.